Search

Your search keyword '"Galazka, A. R."' showing total 110 results
Start Over Author "Galazka, A. R."
110 results on '"Galazka, A. R."'

1. Magnetic contribution to the specific heat of Pb_{1-x}Eu_{x}Te

Author

Gorska, M., Lusakowski, A., Jedrzejczak, A., Golacki, Z., Galazka, R. R., Anderson, J. R., and Balci, H.

Subjects
Condensed Matter - Other Condensed Matter, Condensed Matter - Materials Science
Abstract

The temperature dependence of the magnetic specific heat has been studied experimentally and theoretically in the semimagnetic semiconductor Pb_{1-x}Eu_{x}Te for x=0.027 and x=0.073, over the temperature range from 0.5 K to 10 K, in magnetic fields up to 2 T. There was a maximum in the magnetic specific heat between 1 and 3 K even in zero and low magnetic fields; this maximum shifted toward higher temperatures with increasing magnetic field. The experimental data have been analyzed in the framework of a model in which we assume that the ground states of europium ions are split even without an external magnetic field. We present arguments which support this assumption and we show that it is possible to find a physical mechanism leading to the splitting which can explain the experimental results., Comment: 11 pages, 7 figures, submitted to Physical Review B

Published
2005
Full Text
View/download PDF

2. Antiferromagnetic Interlayer Coupling in Ferromagnetic Semiconductor EuS/PbS(001) Superlattices

Author

Kepa, H., Kutner-Pielaszek, J., Blinowski, J., Twardowski, A., Majkrzak, C. F., Story, T., Kacman, P., Galazka, R. R., Ha, K., Swagten, H. J. M., de Jonge, W. J. M., Sipatov, A. Yu., Volobuev, V., and Giebultowicz, T. M.

Subjects
Condensed Matter
Abstract

Antiferromagnetic coupling between ferromagnetic layers has been observed for the first time in all-semiconductor superlattice structure EuS/PbS(001), by neutron scattering and magnetization measurements. Spin-dependent superlattice band structure effects are invoked to explain the possible origin and the strength of the observed coupling., Comment: 7 pages, 5 figures, submitted to Europhysics Letters

Published
2001
Full Text
View/download PDF

10. Narrow-gap semimagnetic semiconductors

Author

Galazka, Robert R., Kossut, Jacek, Ehlers, J., editor, Hepp, K., editor, Kippenhahn, R., editor, Weidenmüller, H. A., editor, Zittartz, J., editor, Beiglböck, Wlodek, editor, and Zawadzki, Wlodek, editor

Published
1980
Full Text
View/download PDF

11. Shubnikov-de Haas Effect in Hg1−xMnxSe:Fe

Author

Dobrowolski, W., Kossut, J., Witkowska, B., Gałązka, R. R., Cardona, Manuel, editor, Fulde, Peter, editor, von Klitzing, Klaus, editor, Queisser, Hans-Joachim, editor, Lotsch, Helmut K. V., editor, and Landwehr, Gottfried, editor

Published
1989
Full Text
View/download PDF

23. Recombinant human interferon- in the treatment of condylomata acuminata

Author

Dinsmore, Wallace, primary, Jordan, Joe, additional, O'Mahony, Colm, additional, Harris, John R W, additional, McMillan, Alexander, additional, Radcliffe, Keith W, additional, Engrand, Patrick, additional, Jackson, Brian W, additional, Galazka, Andrew R, additional, Abdul-Ahad, Ayad K, additional, and Illingworth, John M, additional

Published
1997
Full Text
View/download PDF

27. Recombinant human interferon-beta in the treatment of condylomata acuminata.

Author

Dinsmore, W, Jordan, J, O'Mahony, C, Harris, J R, McMillan, A, Radcliffe, K W, Engrand, P, Jackson, B W, Galazka, A R, Abdul-Ahad, A K, and Illingworth, J M

Abstract

The number of clinic consultations for condylomata acuminata (genital warts) has increased substantially during the last 30 years. Most infections produce benign lesions but a few types may be associated with cervical and penile cancers. Interferons (IFN) have shown antiviral properties to these infections and IFN-beta in particular has demonstrated a specific cytopathic effect in humans. A total of 124 patients with condylomata acuminata, the majority of whom had failed previous therapy, were treated intralesionally with either recombinant human interferon-beta la (r-hIFN-beta-1a) or placebo. Up to 6 lesions were treated in each patient, and injections were made 3 times per week for a total of 9 injections. The patients were then followed up for 3 months. Efficacy assessments at all time points (day 19, week 6 and month 3) showed a clear advantage for the r-hIFN-beta-1a interferon-beta treatment. Patients receiving r-hIFN-beta-1a showed a greater proportion of treatment success in terms of the complete or partial reduction (at least 50%) of the total area of the treated lesions. The treatment was also well tolerated. Headache, flu-like symptoms and asthenia were more common in patients receiving r-hIFN-beta-1a, but these adverse events were generally mild in severity and rarely led to patient withdrawal. It was concluded that r-hIFN-beta-1a has good efficacy in condylomata acuminata, and therefore presents a useful therapeutic alternative in this hard-to-treat condition. [ABSTRACT FROM AUTHOR]

Published
1997
Full Text
View/download PDF

39. Differences between in vivo and in vitro activation of cancer patient lymphocytes by recombinant interleukin 2: possible role for lymphokine-activated killer cell infusion in the in vivo-induced activation

Author

CARLO GAMBACORTI PASSERINI, Rivoltini, L., Radrizzani, M., Belli, F., Sciorelli, G., Ravagnani, F., Galazka, A. R., Cascinelli, N., and Parmiani, G.

Subjects
Cytotoxicity, Immunologic, Killer Cells, Natural, Lymphokines, Humans, Interleukin-2, Immunotherapy, Lymphocytes, Lymphocyte Activation, Melanoma, Recombinant Proteins, Cell Line
Abstract

In this study 15 consecutive melanoma patients were treated with two courses of bolus recombinant interleukin 2 (rIL2) and rIL2 plus in vitro-generated lymphokine-activated killers (LAK), respectively. The immunological monitoring performed after 4 days of rIL2 or rIL2 plus LAK, indicate that the in vivo peripheral blood lymphocyte (PBL), activation (spontaneous proliferation, tumor cytotoxicity, number of DR+ PBL, obtained after the second cycle of rIL2 plus LAK is significantly higher than after the first cycle of rIL2 alone. During the 5-day interval between the two courses, PBL activation returns to baseline levels and no evidence for increased sensitivity of PBL to rIL2 is present. To further confirm this, two additional patients were studied, in whom rIL2 was administered by continuous i.v. infusion. In these two patients the in vitro versus in vivo PBL activation could be directly and simultaneously compared by using in vitro the same concentration of rIL2 reached and maintained in the patients' sera. The PBL activation induced in vivo by a cycle of rIL2 alone was significantly less (about 10 times) than that obtained in vitro with a comparable rIL2 concentration. Thus, the infusion of in vitro highly activated PBL could explain the increased in vivo lymphocyte activation of the second cycle of rIL2 plus LAK over the first cycle of rIL2 alone.

Catalog

Books, media, physical & digital resources
See catalog results